Compare

Accustem Sciences Inc. vs Semnur Pharmaceuticals, Inc. vs Alzamend Neuro, Inc. vs NeuroSense Therapeutics Ltd.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Accustem Sciences Inc. ACUT	Semnur Pharmaceuticals, Inc. SMNR	Alzamend Neuro, Inc. ALZN	NeuroSense Therapeutics Ltd. NRSN
Year ended	2025-12-31	2025-12-31	2026-04-30	2025-12-31
Revenue	n/a	n/a	n/a	n/a
Revenue growth (YoY)	n/a	n/a	n/a	n/a
Gross margin	n/a	n/a	n/a	n/a
Operating margin	n/a	n/a	n/a	n/a
Net margin	n/a	n/a	n/a	n/a
Net income	-$1.76M	-$160.42M	-$8.77M	-$11.12M
EPS (Diluted)	-$0.12	-$0.78	-$2.63	-$0.44
Operating cash flow	-$850.4K	-$5.87M	-$8.07M	-$7.67M
Free cash flow	n/a	n/a	n/a	-$7.68M
Cash & equivalents	n/a	$20.0K	$710.7K	$166.0K
Total assets	$1.55M	$1.35M	$2.08M	$1.03M
Total liabilities	$4.95M	$22.10M	$1.35M	$2.59M
Shareholders' equity	-$3.40M	-$20.75M	$733.2K	-$1.56M
Return on year-end equity	n/a	n/a	n/m	n/a
Shares outstanding	16.07M	230.21M	4.26M	32.56M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Accustem Sciences Inc.	Semnur Pharmaceuticals, Inc.	Alzamend Neuro, Inc.	NeuroSense Therapeutics Ltd.
Latest	n/a	n/a	n/a	n/a
1 year earlier	n/a	n/a	n/a	n/a
2 years earlier	n/a	n/a	n/a	n/a
3 years earlier	n/a	n/a	n/a	n/a
4 years earlier	n/a	n/a	n/a	n/a